Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Mechanism Behind Tumor Growth And Metastasis Revealed

XTALKS VITALS NEWS

In the early stages of tumor formation, TGF-beta acts as an inhibitory compound by preventing cell division and inducing cell death.

Tweetables from this article:

Tweet: "Only now have researchers identified some of the mechanisms responsible for TGF-beta’s switch"

Share this!

September 9, 2016 | by Sarah Massey, M.Sc.

While previous research has found that transforming growth factor beta (TGF-beta) can both stimulate and suppress cancerous tumor growth and development, the mechanisms behind this were unknown. Now, researchers at Ludwig Institute for Cancer Research at Uppsala University have uncovered some of the details governing this process.

The Ludwig Institute for Cancer Research at Uppsala University has a 30-year history in the study of TGF-beta’s role in cell signaling and tumorigenesis. Only now have researchers identified some of the mechanisms responsible for TGF-beta’s switch from tumor suppression to tumor enhancing.

“Our hope is that these findings will make it possible to discover a way to selectively inhibit the TGF-beta signals that stimulate tumor development without knocking out the signals that inhibit tumor development, and that this can eventually be used in the fight against cancer,” said Eleftheria Vasilaki, postdoctoral researcher at Uppsala University. The results of the research were published in the journal, Science Signaling.



TGF-beta is most active during fetal development where it acts to regulate cell growth and differentiation. The cytokine also plays a complicated role when it comes to tumor growth and development.

In collaboration with a research team in Japan, Vasilaki and colleagues found that TGF-beta works alongside another oncoprotein, Ras, which is often overexpressed in cancer cells. The two proteins suppress p53 protein, which is a key regulator of tumor development.

The suppression of p53 works to enhance the effect of a related protein, delta-Np63, which acts to stimulate cancer development and tumor metastasis. These findings could provide researchers with a better understanding of tumorigenesis, and TGF-beta could become a valuable drug target for the development of cancer therapies.


Keywords: Tumor Growth, Cancer Research, Metastasis


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News


Lung Cancer Recurrence Could Be Better Detected Using Biomarker Blood Test

March 24, 2017 - The results of a recent prospective clinical trial found that a biomarker blood test could detect lung cancer recurrence a full six months before imaging methods could spot the disease.

Featured In: Biotech News


Use of Testosterone Treatments Boosted by DTC Ad Campaigns

March 24, 2017 - Those with a stake in the pharmaceutical industry often question the effectiveness of direct-to-consumer (DTC) advertising, and whether it truly influences consumers to talk to their doctors about medical conditions and perhaps even ask for drugs by name.

Featured In: Pharmaceutical Marketing News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.